DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the stock.

A number of other research firms have also recently commented on DBVT. JMP Securities lifted their price target on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a report on Wednesday, July 31st. HC Wainwright reiterated a buy rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st.

DBV Technologies Trading Up 3.7 %

NASDAQ:DBVT opened at $0.76 on Wednesday. The stock has a market capitalization of $73.55 million, a PE ratio of -0.91 and a beta of 0.68. The firm’s 50 day moving average is $0.88 and its 200 day moving average is $1.14. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $3.02.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the firm posted ($0.26) EPS. Research analysts predict that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.